PDE2A

Chr 11AR

phosphodiesterase 2A

Also known as: CGS-PDE, IDDPADS, PDE2A1, PED2A4, cGSPDE

The protein functions as a cGMP-activated cyclic nucleotide phosphodiesterase that degrades both cGMP and cAMP second messengers, with higher efficiency for cGMP. Biallelic mutations cause intellectual developmental disorder with paroxysmal dyskinesia or seizures, inherited in an autosomal recessive pattern. The gene shows high constraint against loss-of-function variants (LOEUF 0.348), indicating intolerance to protein-disrupting changes.

OMIMResearchSummary from RefSeq, OMIM, UniProt
MultiplemechanismARLOEUF 0.351 OMIM phenotype
Clinical SummaryPDE2A
Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.63) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
2 unique Pathogenic / Likely Pathogenic· 72 VUS of 200 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint
0.35LOEUF
pLI 0.631
Z-score 5.44
OE 0.21 (0.140.35)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint
4.06Z-score
OE missense 0.51 (0.460.56)
271 obs / 535.0 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios
LoF OE0.21 (0.140.35)
00.351.4
Missense OE0.51 (0.460.56)
00.61.4
Synonymous OE0.97
01.21.6
LoF obs/exp: 12 / 55.9Missense obs/exp: 271 / 535.0Syn Z: 0.38
DN
0.5279th %ile
GOF
0.6930th %ile
LOF
0.4627th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
LOFLOEUF 0.35

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

200 submitted variants in ClinVar

Classification Summary

Pathogenic1
Likely Pathogenic1
VUS72
Likely Benign92
Benign10
1
Pathogenic
1
Likely Pathogenic
72
VUS
92
Likely Benign
10
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
1
0
1
Likely Pathogenic
1
0
0
0
1
VUS
5
64
3
0
72
Likely Benign
0
2
45
45
92
Benign
0
0
9
1
10
Total6665846176

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PDE2A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →